CA2103276A1 - Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers - Google Patents

Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers

Info

Publication number
CA2103276A1
CA2103276A1 CA002103276A CA2103276A CA2103276A1 CA 2103276 A1 CA2103276 A1 CA 2103276A1 CA 002103276 A CA002103276 A CA 002103276A CA 2103276 A CA2103276 A CA 2103276A CA 2103276 A1 CA2103276 A1 CA 2103276A1
Authority
CA
Canada
Prior art keywords
tetrazol
biphenyl
imidazole
methyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002103276A
Other languages
English (en)
French (fr)
Inventor
Pancras Chor Bun Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2103276A1 publication Critical patent/CA2103276A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002103276A 1991-05-15 1992-05-14 Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers Abandoned CA2103276A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15
US07/700,740 1991-05-15

Publications (1)

Publication Number Publication Date
CA2103276A1 true CA2103276A1 (en) 1992-11-16

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002103276A Abandoned CA2103276A1 (en) 1991-05-15 1992-05-14 Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers

Country Status (11)

Country Link
EP (1) EP0584250A1 (cs)
JP (1) JP2930252B2 (cs)
AU (1) AU664375B2 (cs)
CA (1) CA2103276A1 (cs)
CZ (1) CZ281570B6 (cs)
IE (1) IE921534A1 (cs)
IL (1) IL101858A (cs)
MX (1) MX9202243A (cs)
NZ (1) NZ242724A (cs)
WO (1) WO1992020342A1 (cs)
ZA (1) ZA923557B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
DE69626958T2 (de) 1995-03-16 2004-03-18 Pfizer Inc. Verwendung von amlodipin, eines seiner salze oder felodipin in kombination mit einem ace-hemmer zur herstellung eines arzneimittels zur behandlung von nicht ischämischer kongestiver herzinsuffizienz
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE69936992T2 (de) 1998-07-10 2008-03-06 Novartis Pharma Ag Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
CA2430924A1 (en) * 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP3045174A1 (en) * 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0565634B1 (en) * 1990-12-14 1999-03-17 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions

Also Published As

Publication number Publication date
CZ281570B6 (cs) 1996-11-13
AU2026992A (en) 1992-12-30
JPH06508128A (ja) 1994-09-14
AU664375B2 (en) 1995-11-16
IL101858A (en) 1996-08-04
NZ242724A (en) 1994-09-27
JP2930252B2 (ja) 1999-08-03
WO1992020342A1 (en) 1992-11-26
MX9202243A (es) 1992-11-01
EP0584250A1 (en) 1994-03-02
EP0584250A4 (cs) 1994-03-30
ZA923557B (en) 1993-11-15
IE921534A1 (en) 1992-11-18
IL101858A0 (en) 1992-12-30
CZ235193A3 (en) 1994-03-16

Similar Documents

Publication Publication Date Title
CA2103276A1 (en) Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers
EP0565634B1 (en) Angiotensin ii receptor blocking compositions
US5958961A (en) Pharmaceutical composition for angiotensin II-mediated diseases
US5492904A (en) Composition of angiotensin-II receptor antagonists and calcium channel blockers
EP0628313B1 (en) Combination of an angiotensin-II antagonising benzimidazole with manidipine for the treatment of hypertension
KR910007927A (ko) 축합 이미다졸 유도체 및 이의 제조방법
HU219404B (hu) Eljárás kardiális és vaszkuláris hipertrófia és/vagy hiperplazia kezelésére alkalmas angiotenzin-II-receptor blokkoló hatású vegyületet tartalmazó gyógyszerkészítmények előállítására
US20030181500A1 (en) Medicinal compositions for the prevention or treatment of cardiac failure
JPH11228410A (ja) イミダゾールアンジオテンシン−ｉｉ受容体拮抗薬からなる慢性腎不全治療剤
IL98794A (en) History of 4-alkyl-2-profile -H) -2 (] -11- tetrazol-5-yl (biphenyl-4-yl) -methyl [imidazole and pharmaceutical preparations containing them
CA2379666C (en) Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
JP3057471B2 (ja) アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
JPH02235822A (ja) 薬物耽溺治療用組成物
SK78994A3 (en) Optic hypotensive agent and method of its preparation
EP1243261B1 (en) Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia
EP0612523B1 (en) Vascular hypertrophy suppressor
KR100222627B1 (ko) 앙기오텐신-ii 수용체 길항제 및 칼슘 채널 차단제의 신규한 조성물
EP0005074A1 (en) A material and composition for reducing blood pressure
JPWO2002092096A1 (ja) 抗腫瘍剤
Boero et al. Verapamil in arterial hypertension with renal disease
JPH01275529A (ja) 晩発性運動障害の抑制治療剤
JP3639982B2 (ja) カルボキシメチリデンシクロヘプトイミダゾ−ル誘導体の易吸収性経口用医薬組成物
Schoenberger Calcium antagonists: use in hypertension evaluation of calcium antagonists in combination with diuretics.
KR20010013014A (ko) 고립성 수축기 고혈압증의 치료 방법
JPH0873352A (ja) 高血圧治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued